ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Abdelrahman M.G. Yousef
Matched on ORCID iD 0000-0001-7761-8149; OpenAlex author ID A5064033799. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2024: 1 paper · 2025: 3 papers · 2026: 1 paper
Papers 5
- Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
- Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
- KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
- KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13045-025-01696-0↗
- Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael James Overman · 4 shared papers, 2024–2026 · strength 0.71
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Matthew H. G. Katz · 4 shared papers, 2024–2026 · strength 0.71
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Robert A. Wolff · 4 shared papers, 2024–2026 · strength 0.71
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Mahmoud Yousef · 4 shared papers, 2024–2026 · strength 0.71
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Rebecca Anne Snyder · 4 shared papers, 2024–2026 · strength 0.71
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Anirban Maitra · 4 shared papers, 2024–2026 · strength 0.71
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Brandon George Smaglo · 4 shared papers, 2024–2026 · strength 0.71
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Shubham Pant · 4 shared papers, 2024–2026 · strength 0.71
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Dan Zhao · 4 shared papers, 2024–2025 · strength 0.69
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-2024↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Ethan Bernard Ludmir · 3 shared papers, 2025–2026 · strength 0.55
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Eugene Jon Koay · 3 shared papers, 2025–2026 · strength 0.55
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Haoqiang Ying · 3 shared papers, 2025–2026 · strength 0.53
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-2024↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Huamin Wang · 3 shared papers, 2024–2025 · strength 0.52
- Paper Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. DOI 10.1093/oncolo/oyae182↗
- Paper KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. DOI 10.1158/0008-5472.can-25-2024↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Jason A. Willis · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Saikat Chowdhury · 3 shared papers, 2024–2026 · strength 0.52
- Paper Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. DOI 10.1093/oncolo/oyag423↗
- Paper KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. DOI 10.1186/s13045-025-01696-0↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0↗
- Ching-Wei David Tzeng · 2 shared papers, 2025 · strength 0.36
- Naruhiko Ikoma · 2 shared papers, 2025–2026 · strength 0.36
- Ryan W. Huey · 2 shared papers, 2025–2026 · strength 0.36
- James C. Yao · 1 shared paper, 2025 · strength 0.19
- Ahmed Elhariri · 1 shared paper, 2026 · strength 0.19
- Dan Zhao · 1 shared paper, 2026 · strength 0.19
- Huamin Wang · 1 shared paper, 2026 · strength 0.19
- Andrea Viale · 1 shared paper, 2025 · strength 0.17
- Ching-Fei Li · 1 shared paper, 2025 · strength 0.17
- Hong Zhao · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.